IOV-3001

IOV-3001 is a modified dimeric interleukin-2 (IL-2) fusion protein engineered as an IL-2 CDR graft fused to palivizumab, designed to have a longer half-life and improved safety profile compared with aldesleukin. It selectively targets IL2R beta-gamma-expressing cells while limiting activation of regulatory T cells (Tregs) that depend on the alpha-beta-gamma receptor complex. This selectivity aims to enhance anti-tumor immune responses by promoting CD8+ T cell expansion and reducing immunosuppressive Treg activity. Preclinical studies demonstrated that IOV-3001 induces robust STAT5 phosphorylation in peripheral blood mononuclear cells (PBMCs) and tumor-infiltrating lymphocytes (TILs), with pharmacodynamic effects consistent with IL-2 receptor-mediated activation. The drug is being developed primarily as part of tumor-infiltrating lymphocyte (TIL) therapy regimens for cancer, particularly melanoma, and has shown favorable preclinical safety data supporting less frequent dosing than traditional high-dose IL-2 therapies[1][2][4][5][7].

Other names

Next generation IL-2 for TIL treatment regimen